Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds ...
Researchers assessed the prognostic significance of older age and comorbidity burden on overall survival in patients with hepatocellular carcinoma.
CLINICAL complete response (cCR) is a strong predictor of prognosis in patients with unresectable hepatocellular carcinoma ...
Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.
This document, on the diagnosis and treatment of patients with hepatocellular carcinoma (HCC), was commissioned by the British Society of Gastroenterology as part of a wider initiative to develop ...
1d
Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...
The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.
Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback